Medpace Holdings, Inc. MEDP revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Medpace Holdings, Inc. reported revenue across 6 products and services; the largest, Oncology, was $748M, 29.5% of the filed sum (+14.8% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Oncology$748M29.5%+14.8% yoy
- Metabolic$745M29.4%+62.8% yoy
- Other$409M16.1%-5.3% yoy
- Central Nervous System$255M10.1%+40.0% yoy
- Cardiology$239M9.5%+3.9% yoy
- Antiviral And Anti Infective$135M5.3%-13.8% yoy
Members sum to the consolidated $2.53B for this period.
- Metabolic$219M31.0%no prior
- Oncology$209M29.6%no prior
- Other$98.3M13.9%no prior
- Central Nervous System$82.9M11.7%no prior
- Cardiology$60M8.5%no prior
- Antiviral And Anti Infective$37.8M5.3%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.